MétaCan
Menu
Back to cohort
Record W4409703085 · doi:10.1177/23969873251334278

Recurrent stroke in patients with history of stroke/transient ischemic attack and device-detected atrial fibrillation: A systematic review and meta-analysis

2025· review· en· W4409703085 on OpenAlexaff
Lina Palaiodimou, Aristeidis H. Katsanos, Konstantinos Melanis, Maria‐Ioanna Stefanou, Michele Romoli, Georgia Papagiannopoulou, Aikaterini Theodorou, Martin Köhrmann, Polychronis Dilaveris, Konstantinos Tsioufis, Gkikas Magiorkinis, Christos Krogias, Marios Themistocleous, Simona Sacco, Mira Katan, Gerasimos Filippatos, Georgios Tsivgoulis

Bibliographic record

VenueEuropean Stroke Journal · 2025
Typereview
Languageen
FieldMedicine
TopicAtrial Fibrillation Management and Outcomes
Canadian institutionsMcMaster UniversityPopulation Health Research Institute
Fundersnot available
KeywordsMedicineStroke (engine)Atrial fibrillationInternal medicineEmbolismMyocardial infarctionRelative riskCardiologyMeta-analysisRandomized controlled trialConfidence interval

Abstract

fetched live from OpenAlex

Abstract Introduction: Prolonged cardiac monitoring after stroke increases the detection of device-detected atrial fibrillation (DDAF), leading to a clinical dilemma regarding anticoagulation for secondary stroke prevention. While anticoagulation reduces thromboembolic risk in clinical AF, its benefit-risk profile in DDAF remains uncertain. Methods: In this systematic review and meta-analysis, randomized-controlled clinical trials (RCTs) evaluating anticoagulation among patients with DDAF post stroke or transient ischemic attack (TIA) were pooled. The primary efficacy outcome was any stroke recurrence, while stroke or systemic embolism, ischemic stroke recurrence, myocardial infarction, and cardiovascular mortality were assessed as secondary efficacy outcomes. The primary safety outcome was major bleeding, while hemorrhagic stroke and all-cause mortality were assessed as secondary safety outcomes. Results: Two RCTs with 599 patients (294 anticoagulation, 305 no-anticoagulation) were included. Anticoagulation significantly reduced any stroke recurrence (RR: 0.47; 95% CI: 0.23–0.94; p = 0.034; number-needed-to-treat = 34). Anticoagulation lowered the risk of the composite outcome of stroke recurrence and systemic embolism (RR: 0.45; 95% CI: 0.22–0.90; p = 0.023). However, anticoagulation was associated with an increased risk of major bleeding (RR: 2.30; 95% CI: 1.06–4.98; p = 0.035; number-needed-to-harm = 37). There were no differences in ischemic stroke recurrence (RR: 0.53; 95% CI: 0.26–1.09; p = 0.084), myocardial infarction (RR: 0.58; 95% CI: 0.17–1.96; p = 0.379), cardiovascular mortality (RR: 0.68; 95% CI: 0.35–1.34; p = 0.265), hemorrhagic stroke (RR: 0.25; 95% CI: 0.03–2.24; p = 0.217) or all-cause mortality (RR: 0.97; 95% CI: 0.66–1.41; p = 0.857). Discussion: Anticoagulation in DDAF patients with prior stroke/TIA reduces any stroke recurrence but increases major bleeding risk without raising hemorrhagic stroke incidence. This trade-off underscores the need for individualized risk stratification. Conclusions: Anticoagulation lowers any stroke recurrence in DDAF patients post-stroke/TIA but raises major bleeding risk.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.022
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.017
Threshold uncertainty score0.044

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.022
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0170.029
Bibliometrics0.0050.006
Science and technology studies0.0010.001
Scholarly communication0.0030.001
Open science0.0020.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.097
GPT teacher head0.336
Teacher spread0.239 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Stroke JournalSame topicAtrial Fibrillation Management and OutcomesFrench-language works237,207